Thoma Bravo is evaluating the sale of Imprivata, which helps healthcare providers protect patient information, according to six people familiar with the situation. A formal process has not yet launched, the people said, but is expected to get underway in the next two to three weeks, one of the people said. Imprivata posted approximately $100 million in 2019 revenue, some of the sources said, while a fourth placed estimated 2020 EBITDA at approximately $140 million.
Read the full article: Thoma Bravo Preps for Potential $2B-Plus Sale of Imprivata //
Source: https://www.pehub.com/thoma-bravo-preps-for-potential-2bn-plus-sale-of-imprivata